Kratom and related 7-OH products have become increasingly accessible through retail outlets and online platforms, sparking regulatory attention from federal authorities. These substances, derived from a tree in the coffee family, are used by millions of Americans, with estimates ranging from 5 million to 15 million lifetime users. While some individuals have relied on kratom to manage opioid addiction or chronic pain, concerns have mounted regarding the addictive properties of highly concentrated formulations, particularly 7-OH products.
7-hydroxymitragynine is one of kratom’s primary psychoactive components, naturally present in small amounts within the plant but concentrated in newer commercial products. These concentrated formulations, which can be sold as tablets, gummies, tonics and chocolates, appear to produce opioid-like effects more prominently than traditional kratom preparations. Case reports indicate some users have experienced severe withdrawal symptoms and required medical intervention when attempting to discontinue use, including sedation-assisted detoxification programs.
Data from poison control centers documented a 1,200% increase in calls related to kratom between 2015 and 2025. A report analyzing 53 U.S. poison control centers identified 233 deaths associated with kratom during that decade, though 79% involved multiple substances. Approximately 62% of reported calls involved individuals using kratom without additional drugs. Regulatory efforts have intensified following these findings, with the Drug Enforcement Administration and Department of Health and Human Services proposing restrictions on concentrated 7-OH and related semi-synthetic opioid products.
The regulatory path has faced significant opposition from kratom advocacy groups and users who credit the substances with enabling long-term opioid recovery and pain management. The American Kratom Association filed legal challenges against enforcement actions. Federal restrictions are expected to focus on highly concentrated formulations rather than traditional botanical kratom products, which are not anticipated to be included in regulatory crackdowns.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI